Atherosclerosis Plus

2021

DOI: 10.1016/j.athplu.2021.09.001

|View full text |Cite

|

Sign up to set email alerts

|

High baseline fetuin-A levels are associated with lower atherosclerotic plaque progression as measured by 3D ultrasound

Philip Sommer¹,

Michael Schreinlechner²,

Maria Noflatscher³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Results1

Discussion1

Introduction1

Citation Types

Supporting

0

Mentioning

3

Contrasting

0

Year Published

2022

2022

2024

2024

Publication Types

Select...

Article6

Relationship

Self Cite1

Independent5

Authors

Journals

Cited by 8 publications

(3 citation statements)

References 38 publications

Supporting

0

Mentioning

3

Contrasting

0

Order By: Relevance

“…Thus, it was shown that in patients with metabolic syndrome, fetuin A levels positively correlate with CRP, and higher biomarker levels are associated with an increased risk of myocardial infarction and ischemic stroke [4]. Other studies have shown that low concentrations of fetuin A can increase inflammation and overproduction of cardiotoxic cytokines such as tumor necrosis factor [10]. Studies conducted exclusively on patients with coronary artery disease indicate an association between low levels of fetuin A and mitral aortic calcification and stenosis [3].…”

Section: Resultsmentioning

confidence: 99%

Gender differences in serum markers of inflammation and platelet activation in patients with non-valvular atrial fibrillation

¹

,

²

,

³

et al. 2023

Med. immunol.

View full text Add to dashboard Cite

The prevalence of atrial fibrillation is high and comparable in both sexes. Such factors as differently expressed blood biomarkers in women and men may play a role in the occurrence of atrial fibrillation and the development of thrombotic complications. To study markers of inflammation and platelet activation in patients with atrial fibrillation of non-valvular origin, receiving anticoagulant therapy and having a history of thrombotic complications and patients with atrial fibrillation without thrombotic complications, depending on the gender of the patients. The study included 22 healthy volunteers and 60 patients diagnosed with atrial fibrillation receiving anticoagulant therapy, of which 21 patients developed thrombotic complications. Serum levels of α2- macroglobulin, hsC-reactive protein, fetuin A, α-1-acid glycoprotein, L-selectin, serum amyloid P, adipsin, and platelet factor 4 were studied on FLEXMAP 3D using Acute Phase diagnostic test systems Panel 3. A comparative study of the content of biomarkers demonstrated an increased concentration of C-reactive protein in men and women in both groups of patients with atrial fibrillation; decrease in fetuin A and L-selectin in the group of women with thrombosis compared with women without thrombotic complications and compared with healthy women. There were no gender differences in the concentration of fetuin A and L-selectin in the group of patients with atrial fibrillation without thrombotic complications and in healthy volunteers. The level of adipsin had no gender differences in the group of patients with atrial fibrillation with thrombosis and in healthy volunteers, however, it was significantly increased in women without thrombosis. The content of platelet factor 4 in women in both groups of patients exceeded the value of this indicator in healthy women; no gender differences were found in the groups of patients with atrial fibrillation. Low levels of fetuin A and L-selectin, with a simultaneous increase in C-reactive protein and platelet factor 4, lead to an increase of prothrombogenic potential and to a change in the balance of pro- and antiinflammatory mediators towards increased inflammation in female patients with atrial fibrillation.

“…Thus, it was shown that in patients with metabolic syndrome, fetuin A levels positively correlate with CRP, and higher biomarker levels are associated with an increased risk of myocardial infarction and ischemic stroke [4]. Other studies have shown that low concentrations of fetuin A can increase inflammation and overproduction of cardiotoxic cytokines such as tumor necrosis factor [10]. Studies conducted exclusively on patients with coronary artery disease indicate an association between low levels of fetuin A and mitral aortic calcification and stenosis [3].…”

Section: Resultsmentioning

confidence: 99%

Gender differences in serum markers of inflammation and platelet activation in patients with non-valvular atrial fibrillation

¹

,

²

,

³

et al. 2023

Med. immunol.

View full text Add to dashboard Cite

The prevalence of atrial fibrillation is high and comparable in both sexes. Such factors as differently expressed blood biomarkers in women and men may play a role in the occurrence of atrial fibrillation and the development of thrombotic complications. To study markers of inflammation and platelet activation in patients with atrial fibrillation of non-valvular origin, receiving anticoagulant therapy and having a history of thrombotic complications and patients with atrial fibrillation without thrombotic complications, depending on the gender of the patients. The study included 22 healthy volunteers and 60 patients diagnosed with atrial fibrillation receiving anticoagulant therapy, of which 21 patients developed thrombotic complications. Serum levels of α2- macroglobulin, hsC-reactive protein, fetuin A, α-1-acid glycoprotein, L-selectin, serum amyloid P, adipsin, and platelet factor 4 were studied on FLEXMAP 3D using Acute Phase diagnostic test systems Panel 3. A comparative study of the content of biomarkers demonstrated an increased concentration of C-reactive protein in men and women in both groups of patients with atrial fibrillation; decrease in fetuin A and L-selectin in the group of women with thrombosis compared with women without thrombotic complications and compared with healthy women. There were no gender differences in the concentration of fetuin A and L-selectin in the group of patients with atrial fibrillation without thrombotic complications and in healthy volunteers. The level of adipsin had no gender differences in the group of patients with atrial fibrillation with thrombosis and in healthy volunteers, however, it was significantly increased in women without thrombosis. The content of platelet factor 4 in women in both groups of patients exceeded the value of this indicator in healthy women; no gender differences were found in the groups of patients with atrial fibrillation. Low levels of fetuin A and L-selectin, with a simultaneous increase in C-reactive protein and platelet factor 4, lead to an increase of prothrombogenic potential and to a change in the balance of pro- and antiinflammatory mediators towards increased inflammation in female patients with atrial fibrillation.

“…Previously, we have shown that baseline levels of the acute phase protein neutrophil gelatinase-associated lipocalin (NGAL), but not hsCRP, correlate directly with TPV as measured by 3D ultrasound [27]. Baseline levels of fetuin-A, a serum protein involved in calcium homeostasis and inflammation, but not hsCRP, correlated inversely with TPP [28]. Using a pre-specified endpoint, we show that measurements of sP-selectin levels over time predict the progression of peripheral atherosclerosis and improve the predictive value of the ESC-SCORE in a multiple logistic model.…”

Section: Discussionmentioning

confidence: 96%

“…Recently, automated software capable of precisely quantifying plaques has been developed, which makes the exact quantification of plaque volume within a relatively short time possible. Previous publications show that 3D plaque volumetry is a useful tool for the evaluation of cardiovascular biomarkers [27,28]. Here we report the association between sP-selectin and peripheral atherosclerotic plaque progression, which had been designed as a prespecified endpoint of our study.…”

Section: Introductionmentioning

confidence: 93%

Increasing Soluble P-Selectin Levels Predict Higher Peripheral Atherosclerotic Plaque Progression

Sommer,

Schreinlechner,

Noflatscher

et al. 2023

Self Cite

View full text Add to dashboard Cite

Background and aims: The adhesion molecule P-selectin is expressed by endothelial cells and platelets. It is involved in platelet activation and leukocyte adhesion, both important processes in the pathogenesis of atherosclerosis. Our study was designed to assess the predictive value of soluble P-selectin (sP-selectin) on the progression of peripheral atherosclerosis. Methods: This is an observational, single-center, cohort study that included 443 patients with established cardiovascular disease (CVD) or at least one cardiovascular risk factor. Over a period of 4 years, each patient underwent three-dimensional (3D) ultrasound to assess the plaque volume of the carotid and femoral arteries once per year. In addition, plasma sP-selectin levels were measured at each visit. The association between changes in sP-selectin and peripheral atherosclerotic plaque progression was assessed using growth curve models. Results: 338 patients were available for statistical analysis. Each standard deviation increase in sP-selectin was significantly (p < 0.001) associated with a 46.09 mm3 higher plaque volume. In ROC-analysis, changes in sP-selectin over time showed an optimal cut-off value around Δ 0.0 µg/mL sP-selectin and significantly improved the predictive value of the ESC-SCORE (AUC for the combination of both parameters was 0.75 (95% CI 0.68–0.81, p < 0.001). Patients with increasing sP-selectin showed a significantly higher plaque progression compared to patients with decreasing or stable sP-selectin levels (202 mm3 vs. 110 mm3, p < 0.001). Conclusions: Increasing sP-selectin levels can predict higher atherosclerotic plaque progression as measured by 3D ultrasound. We suggest serial measurements of sP-selectin as an easily measurable biomarker for peripheral atherosclerotic plaque progression.

Hepatocyte growth factor as indicator for subclinical atherosclerosis

Sommer,

Schreinlechner,

Noflatscher

et al. 2024

View full text Add to dashboard Cite

Summary: Background and aims: Hepatocyte growth factor (HGF) is a pleiotropic cytokine mainly produced by mesenchymal cells. After endothelial damage by oxidized low-density lipoprotein (LDL), HGF is produced and released into the circulation in response. Due to this mechanism HGF has been proposed as possible clinical biomarker for clinical as well as subclinical atherosclerosis. Methods: The conducted study is an observational, single centre, cohort study, including 171 patients with at least one cardiovascular risk factor or already established cardiovascular disease (CVD). Each patient underwent 3D plaque volumetry of the carotid and femoral arteries as well as physical examination and record of the medical history. Additionally, plasma HGF and further laboratory parameters like high sensitivity C-reactive protein and LDL-cholesterol were determined. Results: 169 patients were available for statistical analysis. In bivariate correlation, HGF showed a highly significant correlation with total plaque volume (TPV, r=0.48; p<0.001). In receiver operating characteristic (ROC) analysis for high TPV, HGF showed an area under the curve (AUC) of 0.68 (CI 95%: 0.59–0.77, p<0.001) with a sensitivity of 78% and a specificity of 52% to predict high TPV at a cut-off of 959 ng/ml. In the ROC-analysis for the presence of CVD, HGF demonstrated an AUC of 0.65 (95% CI 0.55–0.73; p=0.01) with a sensitivity of 77% and a specificity of 52%. Conclusions: Higher plasma levels of HGF are associated with higher atherosclerotic plaque volume as measured by 3D-ultrasound.

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Product

Browser Extension Assistant by scite Citation Statement Search Reference Check Visualizations Dashboards Explore Journals Explore Organizations Explore Funders Embedding Badge Embedding Citation Search Pricing

Resources

Blog Help & FAQ Accessibility Statement API Terms For Universities & Governments For Researchers For Publishers For Corporate, Pharma & Enterprise Author Marketing Become an Affiliate Get an organization trial or quote scite Data & Services

About

News & Press Careers Read our Paper Coverage

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Copyright © 2024 scite LLC. All rights reserved.

Made with 💙 for researchers

Part of the Research Solutions Family.